Format

Send to

Choose Destination
Expert Opin Pharmacother. 2017 Sep;18(13):1311-1323. doi: 10.1080/14656566.2017.1361408. Epub 2017 Aug 7.

Small molecules as therapy for uveitis: a selected perspective of new and developing agents.

Author information

1
a Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health , Department of Ophthalmology , Campus Virchow Klinikum, Berlin , Germany.
2
b Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health , Institute of Clinical Pharmacology and Toxicology , Berlin , Germany.
3
c Department of Clinical Pharmacy, Faculty of Pharmacy , Ain Shams University , Cairo , Egypt.
4
d Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health , Department of Rheumatology and Clinical Immunology , Berlin , Germany.

Abstract

Intraocular inflammation (uveitis) remains a significant burden of legal blindness. Because of its immune mediated and chronic recurrent nature, common therapy includes corticosteroids, disease-modifying anti-rheumatic drugs and more recently biologics as immune modulatory agents. The purpose of this article is to identify the role of new treatment approaches focusing on small molecules as therapeutic option in uveitis. Areas covered: A MEDLINE database search was conducted through February 2017 using the terms 'uveitis' and 'small molecule'. To provide ongoing and future perspectives in treatment options, also clinical trials as registered at ClinicalTrials.gov were included. Both, results from experimental as well as clinical research in this field were included. Since this field is rapidly evolving, a selection of promising agents had to be made. Expert opinion: Small molecules may interfere at different steps of the inflammatory cascade and appear as an interesting option in the treatment algorithm of uveitis. Because of their highly targeted molecular effects and their favorable bioavailability with the potential of topical application small molecules hold great promise. Nevertheless, a careful evaluation of these agents has to be made, since current experience is almost exclusively based on experimental uveitis models and few registered trials.

KEYWORDS:

Adhesion molecules; JAK/STAT inhibitor; aldose reductase inhibitor; alpha 4 integrin inhibitor; dihydroorotate dehydrogenase inhibitor; mTOR inhibitor; phosphodiesterase inhibitor; small molecule; sphingosine-1 phosphate receptor 1 antagonist; uveitis

PMID:
28750572
DOI:
10.1080/14656566.2017.1361408
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center